NurExone Biologic Reported In-line with Estimates

NurExone Biologic (NRXBF) reported a loss of $0.02 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.02 per share. The company reported in-line with consensus estimates.

NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic Inc. is based in HAIFA, Israel.